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A B S T R A C T
Purpose: Status epilepticus (SE) is a life-threatening condition that can be refractory to initial treatment.
Randomized controlled studies to guide treatment choices, especially beyond ﬁrst-line drugs, are not
available. This report summarizes the evidence that guides the management of refractory convulsive SE
(RCSE) in children, deﬁnes gaps in our clinical knowledge and describes the development and works of
the ‘pediatric Status Epilepticus Research Group’ (pSERG).
Methods: A literature review was performed to evaluate current gaps in the pediatric SE and RCSE
literature. In person and online meetings helped to develop and expand the pSERG network.
Results: The care of pediatric RCSE is largely based on extrapolations of limited evidence derived from adult
literature and supplemented with case reports and case series in children. No comparative effectiveness
trials have been performed in the pediatric population. Gaps in knowledge include risk factors for SE,
biomarkers of SE and RCSE, second- and third-line treatment options, and long-term outcome.
Conclusion: The care of children with RCSE is based on limited evidence. In order to address these
knowledge gaps, the multicenter pSERG was established to facilitate prospective collection, analysis, and
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Status epilepticus (SE) is one of the most common neurologic
emergencies of childhood.1–4 A major proportion of morbidity and
mortality associated with SE occurs during episodes of refractory
convulsive status epilepticus (RCSE),5–8 a condition characterized
by the persistence of convulsive seizures or evolution of the
convulsive seizure to non-convulsive seizures despite initial,
antiepileptic medication treatment.7 This review aims to describe
the main characteristics of pediatric RCSE, emphasizing opportu-
nities to better understand and eventually improve care.
2. Literature search method
Since there is no MeSH term corresponding to refractory status
epilepticus, we performed a PubMed search using a semi-
structured string (‘‘Status epilepticus’’ [Mesh] AND ‘‘refractory’’)
in August 2013. The ﬁlter ‘‘age’’ was applied to include all patients
18 years. The initial search returned 268 papers. Additional 127
papers were identiﬁed from relevant articles known to the
members of pSERG and a manual search of cited references. After
screening and exclusion of abstracts (and when relevant, full-text
manuscripts), 113 articles were included in this literature review
(Fig. 1). Because randomized clinical trials in pediatric status
epilepticus patients are rare, we also included randomized clinical
trials performed exclusively or predominantly in adults in this
systematic review.
3. Deﬁnitions
When medications fail to terminate SE, it is often termed
refractory. However, although to date, there is no single, accepted
operational deﬁnition of SE a consensus has developed that SE
should be considered refractory after failure of an initial# of record s ident ified  through 
database searching:  268 
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Fig. 1. Approach to literature review in our manuscript. This ﬁgure outlines tbenzodiazepine followed by another class of antiepileptic drug9
(Table 1).
3.1. Clinical presentation and evolution
When seizures persist for more than 5–10 min the preferred
term is impending SE. When seizures persist for at least 30 min the
preferred term is established SE.10 The prolonged seizures of SE can
evolve from a period of isolated seizures that become progressively
longer and then fuse into a prolonged continuous seizure or
continue to be repeated frequently enough so that a return to
baseline does not occur between the seizures. Eventually, if the SE
persists, a phase of electromechanical dissociation may pursue.
Super-refractory SE is deﬁned as SE that continues 24 h or more
after the onset of anesthetic therapy for SE, including those cases in
which SE recurs during reduction or withdrawal of anesthesia.11
Additionally, SE has been also classiﬁed based on clinical
features, such as convulsive SE or non-convulsive SE. Deﬁning
convulsive SE as a convulsive seizure that lasts for a period of at
least 5 min is not only practical9,12 but is supported by the ﬁnding
that the probability of a seizure stopping spontaneously without
intervention is quite low after this duration.13
3.2. Pathophysiology and etiology
One of the difﬁculties in developing a comprehensive deﬁnition
of SE is related to the limited understanding of the pathogenesis of
this neurological emergency. Recent advances outlining the
cellular and molecular changes that occur during SE have focused
on trafﬁcking of receptors14–17 and ion channels.18,19 Yet, time
course studies of these changes are limited and whether these
changes reﬂect the consequences of an episode of SE or are
necessary for an episode of SE to occur is not known, and etiologies
are frequently multifactorial.itional re cord s ident ified 
gh other  sourc es: 127
s 
4 # of record s excluded: 218
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he literature review in this manuscript that follows the PRISMA scheme.
Table 1
Representative deﬁnitions of refractory status epilepticus in previous literature and comparison with our current deﬁnition.
Author and year Deﬁnitions of refractory status epilepticus (SE)
Jagoda and Riggio, 1993 [111] Cases in which seizure control is not attained with a benzodiazepine, phenytoin, and/or phenobarbital
and thus requires the addition of a third-line antiepileptic drug
Lowenstein and Alldredge, 1998 [109] SE that does not respond to a benzodiazepine, phenytoin, or phenobarbital is considered refractory
Stecker et al., 1998 [112] All of the following criteria: (1) acute seizures persisting more than 2 h despite treatment with ﬁrst-line
antiepileptic drugs, (2) altered mental status, and (3) seizures recurring at a rate of at least two per hour
without a recovery to baseline between seizures
Hanley and Kross, 1998 [113] Sustained seizures that do not respond to initial drug therapy and persist longer than 60 min
Mayer et al., 2002 [7] Seizures lasting longer than 60 min despite treatment with a benzodiazepine and an adequate loading dose
of a standard intravenous antiepileptic drug
Loddenkemper and Goodkin, 2011 [21] SE is considered refractory at the latest after failure of the second medication
Rossetti and Lowenstein, 2011 [20] SE that continues despite treatment with benzodiazepines and one antiepileptic drug
Brophy et al., 2012 [9] Refractory SE is considered when either clinical or electrographic seizures persist after receiving adequate doses of
an initial benzodiazepine followed by a second acceptable antiepileptic drug
Present study Prolonged seizures that fail to terminate after administration of two antiepileptic drugs with different mechanisms
of action or that require continuously administered medication to abort seizures, regardless of seizure duration
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There are many different deﬁnitions for refractory SE, almost as
many as manuscripts that have studied this topic (Table 1).
Commonly, refractoriness is considered after failure of at least two
appropriately chosen and administered antiepileptic drugs.9,20,21
Based on this frequently used criterion, our group agreed to term
SE refractory when SE does not respond to two different drugs with
different mechanisms. The second deﬁnition meeting consensus
with pSERG was use of a continuous infusion of AED regardless of
the number or type of previously administered AEDs since this
approach is usually used after failure of at least two different
medications with two different mechanisms of action. Table 1
summarizes representative deﬁnitions of RCSE.
4. Epidemiology of pediatric convulsive status epilepticus
4.1. Incidence
The incidence of convulsive SE in children is approximately
10–27/100,000 per year, with the highest incidence in children less
than one year of age.1–4 If febrile SE is excluded, the incidence
decreases by 25–40%.4 The proportion of cases with RCSE is
difﬁcult to estimate because deﬁnitions vary. In a series of
193 children with SE, 26% had seizures lasting longer than 1 h.22
Duration correlated with etiology: seizures lasting over 1 h
occurred in 46% of patients with acute symptomatic seizures
and in 17% of those with unprovoked seizures.22
4.2. Etiology
Most episodes of RCSE begin in previously healthy children in
the out-of-hospital setting. A large prospective study of 226
children with convulsive SE of a median duration of 65 min in
North London in the United Kingdom, found that 78% of cases
were ﬁrst-ever episodes of SE. Of those, 56% of patients had
normal neurodevelopment at baseline, no history of epilepsy,
and no neurological deﬁcits prior to the SE episode.3 Of theTable 2
Frequency of the most common etiologies of status epilepticus in children.
Febrile
seizures (%)
Acute metabolic derangeme
central nervous system infe
Chin et al., 2006 (N = 226) [3] 33 17 
De Lorenzo et al., 1996 (N = 166) [28] 52a
Singh et al., 2010 (N = 144) [23] 32 9 
a Infections with fever.176 ﬁrst-ever episodes, 77% started out-of-hospital.3,23,24 The
most common cause of pediatric SE is febrile/infectious. The most
common etiologies of SE in children are summarized in Table 2.
The younger the patients, the more frequent an acute symptom-
atic etiology was found, especially in those under one year of
age.3 It is unknown why some febrile processes are associated
with SE while others are not. Infection with the human
herpesvirus 6 (HHV6) and herpesvirus 7 (HHV7) are being
postulated as an additional potential risk factor for the
development of SE and subsequent epilepsy in selected
cases.25,26 Gaps in information exist in the correlation between
etiology, response to different treatment and long-term outcome
after pediatric SE.
4.3. Genetics
A variety of genetic factors might promote or protect patients
from developing uncontrolled seizures.27 Genetic variants that
predispose some individuals to prolonged seizures are yet to be
discovered. A study on concordance rates for SE found a much
higher rate in monozygotic than in dizygotic (0.38 versus 0)
twins.27 However, there are insufﬁcient data to support or refute
routine genetic testing (chromosomal or molecular studies) in
children with SE.24
4.4. Outcome
Children with SE have an overall mortality rate of approxi-
mately 0–3%,3,22,23,28–31 and surviving children are at risk of
lifelong sequelae including cognitive and neurodevelopmental
impairments, new-onset epilepsy, and recurrent SE.22,32 RCSE is
associated with a much higher mortality. In a retrospective series
of 22 children (4.5 months to 18 years of age) with RCSE (refractory
to a benzodiazepine followed by either phenytoin or phenobarbi-
tal, and lasting more than 60 min), mortality was 32%.8 Studies on
RCSE in adults also point toward a higher mortality when SE is
refractory, although it probably reﬂects a more severe underlying
cause.33nt or
ction (%)
Remote
symptomatic (%)
Acute symptomatic on
remote symptomatic (%)
Low antiepileptic
drug levels (%)
16 16
39 21
18
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mortality.8,22 In a series of 193 children with SE, neurologic
sequelae occurred in 29% of infants younger than one year of age,
11% of children one to three years of age, and 6% of children older
than three years of age.22 Given that there was no difference in
outcome when these data were stratiﬁed by etiology, these data
reﬂect the greater incidence of acute neurologic disease (associat-
ed with worse outcome) in younger age groups.22 Long-term
mortality data suggest that the etiology of SE is one of the main
predictors of long-term survival.34 Apart from mortality, SE
survivors have an increased risk of subsequent epilepsy, which
is reported in 13–74%.31 SE recurs in approximately 20% of cases
within four years of initial presentation, with most recurrences
during the ﬁrst two years.31 Seizures and SE recurrence risk is
inﬂuenced by the underlying etiology, with structural or metabolic
lesions associated with the highest risk.31 In addition, current
literature suggests subtle neurocognitive dysfunction in patients
who have suffered a prior episode of SE, but the impact of etiology,
duration and other potential confounders has not been clari-
ﬁed.31,35
There are gaps in data on outcome after pediatric SE.
Speciﬁcally, there are limited data on the mortality and morbidity
following RCSE. There is also scarce information on the relationship
between SE duration and outcome, and on the long-term sequelae
(in particular neurocognitive impairment) of pediatric patients
following RCSE.
5. Current diagnostic strategies in pediatric status epilepticus
Diagnostic testing in children and adolescents with SE varies
among centers and likely reﬂects the limited evidence supporting
most diagnostic approaches in pediatric SE. Although blood
cultures and a lumbar puncture have a high yield in children
with SE and a clinical suspicion of infection, there is insufﬁcient
evidence to either support or refute whether these procedures
should be routinely performed in children in whom there is no
clinical suspicion of infection.36 In addition, the clinical suspicion
of infection is variably deﬁned among studies and the yield of an
infectious work-up has not been studied speciﬁcally for RCSE. The
indications for performing toxicology screening or metabolic
testing in children with SE have not been delineated.24 Evidence to
support the performance of most diagnostic tests relies on limited
data collected in heterogeneous settings with different study
objectives.24 A large set of pediatric RCSE patients with homoge-
neous inclusion criteria may be able to address this gap in
evidence-based practice and will provide valuable information
regarding the diagnostic yield of different tests.
6. Current treatment strategies in pediatric status epilepticus
SE can be refractory to ﬁrst- and second-line medications.
Treatment choices, especially beyond ﬁrst- and second-line
choices, that is treatment choices for RCSE, are often made without
class I evidence.
6.1. Current treatment strategies for SE
The treatments of choice during the ﬁrst half of the twentieth
century included paraldehyde, phenobarbital, and sodium amytal.37
These medications became the established treatment of SE at a time
when options were limited.38 A more recent era of treating SE began
soon after the discovery and synthesis of benzodiazepines in the late
1950s.37 Medical convention suggested a stepwise treatment of
SE9,21,39 and RCSE40 in children. Based on available studies, mostly
performed in adults, and mostly at a time when intravenous
medications and options were limited, the preferred ﬁrst-linetherapy is usually a benzodiazepine, most commonly lorazepam.
Benzodiazepines have been shown to be safe ﬁrst-line treatments in
the in- and out-of-the-hospital setting.3,41,42 If benzodiazepines fail
to terminate SE, many reports describe the use of fosphenytoin (or
phenytoin) or phenobarbital.9,21,39 After failure of the second- or
third-line medication, continuous administration of antiseizure
medications such as midazolam or pentobarbital is advocated by
established medical convention9,21,39 (Supplementary Fig. S1).
However, use of these continuous infusions are not without
untoward effect.43,44 It is unclear if adherence to SE treatment
protocols inﬂuence outcome.45
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.seizure.
2013.10.004.
6.2. Evidence to support ﬁrst-line treatment with benzodiazepines in
children
The administration of 0.5–1 mg/kg of rectal diazepam solution
results in therapeutic concentrations within minutes, which makes
it useful for SE treatment.46 The few controlled studies that have
compared the efﬁcacy of different ﬁrst-line treatments for SE have
either not included children,41,42,47,48 or children represented only
a minor proportion of the study population (16% of patients were
younger than 20 years in a large series of 893 patients).49
The Veterans Affairs (VA) cooperative trial has a randomized
treatment trial that aimed to determine optimal ﬁrst-line
treatment in SE comparing four choices: intravenous diazepam
followed by intravenous phenytoin, intravenous lorazepam,
intravenous phenobarbital, and intravenous phenytoin.41 In that
study lorazepam was superior to phenytoin, but in an intention-to-
treat analysis there were no differences among the four treatment
groups.41 The conclusions from the VA cooperative trial are often
extrapolated to the management of children with SE even though
there were no children in the study.41 In a double-blind study of SE
in 78 adults with 81 episodes seizures were controlled in 76% of the
episodes treated with 10 mg of diazepam intravenously and in 89%
treated with 4 mg of lorazepam intravenously.42 Adverse effects
occurred in 12.5% of the diazepam-treated patients and in 13% of
the lorazepam-treated patients.42 In a series of 205 adults with
out-of-hospital SE, patients were randomized to receive intrave-
nous lorazepam, intravenous diazepam, or intravenous placebo.47
On arrival at the emergency department SE was terminated in
more patients treated with lorazepam (59.1%) or diazepam (42.6%)
than with placebo (21.1%).47
Several studies show efﬁcacy of benzodiazepines as ﬁrst-line
treatment of pediatric SE without a clear beneﬁt of one
benzodiazepine over the others.50 In a series of 77 children and
young adults with SE or serial seizures, lorazepam stopped seizures
in 79% and decreased seizure intensity in an additional 4%.51 In a
prospective study, 44 children (6 months to 5 years of age) were
treated with rectal diazepam during 59 generalized seizures with a
rate of seizure resolution of 80%.52 In 10% rectal diazepam failed,
while intravenous diazepam was effective, and in 10% diazepam
failed after rectal and intravenous administration.52 The thera-
peutic effect was signiﬁcantly correlated with the duration of
convulsions before treatment: early treatment (convulsions
15 min) had effect in 96%, and late treatment (convulsions
>15 min) had effect in 57% of the cases.52 No respiratory
depression or serious side effects were observed.52 In a random-
ized trial of 178 children with convulsive SE (deﬁned as convulsive
activity lasting for 5 min or more), intravenous lorazepam was
compared to the combination of diazepam and phenytoin with no
differences between the treatment groups and 100% seizure
control in both groups.53 This response rate, however, does not
match experiences from others with less than 100% response rate
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bias.53 Diazepam and lorazepam showed no difference in efﬁcacy
in a series of 48 children with SE treated in the emergency
department.54 In a series of 76 episodes of pediatric seizures
lasting more than 5 min, three bolus doses of intravenous
midazolam controlled 89% of the events with minimal chance of
additional response with further drug boluses.55 A meta-analysis
demonstrated that non-intravenous midazolam was at least as safe
and effective as diazepam administered by different routes.56 A
series of 28 children (5–19 years of age) with severe epilepsy who
presented with seizures of more than 5 min duration, were
randomized to receive buccal midazolam or rectal diazepam.57 In
this series, buccal midazolam was shown to be at least as effective
as rectal diazepam.57 A series of 92 children with seizures did not
ﬁnd differences in efﬁcacy between intranasal midazolam and
rectal diazepam as a ﬁrst-line treatment.58 In a series of 24 children
with convulsive seizures of more than 10-min duration, intramus-
cular midazolam was administered earlier and led to more rapid
cessation of seizures than intravenous diazepam.59
Lorazepam is commonly recommended over other benzodiaze-
pines. For children, this recommendation is essentially based on the
large North London series of 182 pediatric patients (1 month to 16
years of age) with convulsive SE, in which treatment with
intravenous lorazepam was associated with a 3.7 (95%CI 1.7–7.9)
times greater likelihood of seizure cessation than was treatment
with rectal diazepam.6However, a recent series of 893 patients (145
of them younger than 20 years of age) demonstrated that
intramuscular midazolam is at least as safe and effective as
intravenous lorazepam.49 Gaps in knowledge include comparative
effectiveness and randomized trial data of ﬁrst-line treatment of
pediatric SE.
6.3. Evidence to support second- and third-line treatment options in
children
The available evidence supporting the use of any particular
second- or third-line therapy is weaker than for ﬁrst-line therapies.
Likely more reports on the use of benzodiazepines, phenobarbital,
and phenytoin for SE exist, because these medications were, until
recently, the only available antiepileptic drugs. In a series of 122
children with generalized convulsive SE treated with a stepwise
combination of a midazolam bolus followed (if needed) by
phenytoin followed (if needed) by a continuous infusion of
midazolam showed that seizures stopped with midazolam given
as a bolus in 58 patients (percentage: 48%). When phenytoin was
added to the midazolam bolus, it stopped seizures in 19 additional
patients (cumulative percentage: 63%), and with continuous
midazolam added to midazolam bolus and phenytoin seizures
stopped in another 32 patients (cumulative percentage: 89%).60
In the North London series of 182 pediatric patients (ages 1
month to 16 years) with convulsive SE, treatment with
intravenous phenytoin as a second-line therapy was associated
with a 9 (95%CI 3–27) times greater likelihood of seizure
cessation as compared to treatment with rectal paraldehyde.6
Yet, a study of 68 pediatric and adult patients with convulsive SE
randomly assigned phenytoin or valproate demonstrated higher
efﬁcacy for valproate.61 In this study phenytoin or valproate were
given as ﬁrst-line drugs without previous administration of
benzodiazepines and only 12 patients (17.6%) in this series were
under 15 years of age.61
A series of 167 patients with SE (deﬁned as continuous
occurrence of seizures for more than 5 min or repeated epileptic
seizures without intercurrent baseline recovery) compared phe-
nytoin, valproate, and levetiracetam as second-line drugs (after
administration of benzodiazepines).62 This study showed that
valproate was more effective than levetiracetam while there wasno difference in the efﬁcacy of phenytoin compared to valproate or
phenytoin compared to levetiracetam.62 However, no patients
younger than 16 years were included in this series.62 A study of 48
patients with convulsive SE refractory to prior treatment with
diazepam and phenobarbital found that seizures were controlled
in 87.5% of patients after valproate administration.63 Only ﬁve
patients (10.4%) in this study were under 15 years of age.63 In
another series of 60 children with generalized convulsive seizures
lasting more than 5 min that did not respond to a bolus of
intravenous diazepam were randomly assigned to either pheno-
barbital or valproate.64 In this study, there was a tendency toward
a higher rate of seizure cessation with valproate than with
phenobarbital (90% versus 77%) with fewer associated adverse
events (24% versus 74%).64
A developing, comparative, randomized, controlled trial intends
to investigate whether valproate and levetiracetam are superior to
phenytoin as second-line treatment options of SE.65 The extrapo-
lation of safety results from adult series directly into children can
be misleading for valproate, which disrupts organic acid metabo-
lism, and therefore can lead to serious toxicity in children with
underlying metabolic disorders (often unknown at the time of SE
presentation) and in children under two years of age.66
In a series of 53 episodes of convulsive SE in 37 children,
lidocaine achieved seizure control in 36%.67 In a series of 53
episodes of prolonged tonic-clonic seizures in 30 children, rectal
paraldehyde terminated convulsions in 63%.68
In summary, there is limited evidence to guide the choice
regarding commonly used second- and third-line treatment
options for pediatric SE. The answer to this problem is further
compounded by the broadening of choice as a result of new
intravenous preparations of antiepileptic drugs such as valproate,
levetiracetam, or lacosamide.
6.4. Evidence to support continuous infusion options in children
Administering continuous infusions of medications at anes-
thetic doses in RCSE is considered after failure of previous
treatments. Current evidence supports benzodiazepines as the
most efﬁcacious and safe continuous infusion in children. In a
series of 20 children with SE, continuous infusion of midazolam
controlled seizures in 19 children after a mean time interval of
0.9 h after treatment initiation.69 In a study of 27 children (8
months to 14 years of age) with RCSE (persistence of seizures for
longer than 60 min despite receiving at least diazepam, phenytoin,
and phenobarbital) a continuous infusion of midazolam controlled
seizures in 26 cases within 65 min of the start of the midazolam
infusion.70 In another series, 40 children (2–12 years of age) with
SE refractory to diazepam bolus and phenytoin were randomized
to a continuous infusion of diazepam or midazolam.71 Control of
RCSE (89% of patients on diazepam and 86% of patients on
midazolam) and median time to seizure control (16 min in both
groups) were not different.71 However, more seizures recurred in
the midazolam group (57%) than in the diazepam group (16%).71
Infusion of benzodiazepines was associated with a low rate of
adverse effects.69–71
Even less information is available on other types of continuous
infusion and anesthetic therapies. Three pediatric patients with
RCSE responded to moderate hypothermia and thiopental-induced
coma.72 Propofol in continuous infusion controlled 14 out of 22
episodes of RCSE in children.73 In the same study, thiopental in
continuous infusion controlled 11 out of 20 episodes of SE.73
Thiopental was associated with more frequent, severe side effects
than propofol and based on these data the authors recommended
use of propofol over thiopental.73 Despite this recommendation,
it is important to be aware that propofol has been associated
in children with lactic acidosis, lipemia, rhabdomyolysis and
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infusion syndrome.74
Pentobarbital is another option for a continuous infusion.75 In a
retrospective series of 30 children with refractory SE treated with
continuous pentobarbital infusion, 33% of patients achieved
sustained burst suppression without relapse during treatment,
67% experienced relapse of epileptiform activity during treatment,
but 60% of those eventually achieved burst suppression with
pentobarbital.76 The rate of adverse effects with pentobarbital
infusion was particularly high with hypotension requiring
inotropes in 93% of patients, an infection in 66%, metabolic
acidosis in 10%, and pancreatitis in 10%.76 Isoﬂurane has also been
reported to be effective in pediatric SE.77
In summary benzodiazepines appear to be the safest and most
frequently used continuous infusion, but literature on this topic is
scarce, indicating a gap in knowledge, and a comparison of efﬁcacy
of different continuous infusions is not available.
6.5. Emerging therapies
Several alternative therapies for RCSE have been reported as
effective in individual patients or small series, but larger
conﬁrmatory trials are not available in children. Topiramate
loading was able to control seizures in a series of three children
with refractory SE.78 The ketogenic diet has been reported as
efﬁcacious in a limited number of children with refractory
nonconvulsive79 and convulsive80 SE. Several cases of refractory
SE have responded to hypothermia both in adults81 and children.82
Preliminary case series suggest that epilepsy surgery may be an
effective alternative in children with refractory SE not responsive
to conventional treatment and with an identiﬁable focus.83 Brain
stimulation is emerging as a potentially useful therapy for
refractory epilepsy. Invasive brain stimulation methods such as
vagus nerve stimulation and deep brain stimulation84 are
presently options to be considered as well as the non-invasive
transcranial magnetic stimulation.85 A common limitation to the
proper evaluation of emerging therapies is the rarity of their use.
This leads to case reports and small series with probable
publication bias of more positive results. Only a large multicenter
study of reference centers will gather enough information to
provide an objective evaluation of these treatments.
6.6. Summary of the evidence on management of status epilepticus in
children
While most SE management protocols advise a stepwise
treatment (Supplementary Fig. S1),86 the data to support the
order of medications in this approach and the stepwise sequence is
scarce, and mostly restricted to ﬁrst-line drugs.9 The best evidence
coming from multiple, large, randomized clinical trials or meta-
analysis is limited to essentially analysis of benzodiazepines,
fosphenytoin (or phenytoin), phenobarbital, and valproate given as
initial treatments in those studies.9 The more refractory the SE
becomes, the less scientiﬁc data exist to support any particular
treatment choice.
An example that illustrates the limited scientiﬁc evidence is the
lack of studies that compare fosphenytoin (or phenytoin) with
phenobarbital as second-line medication,87 although both med-
ications have been widely used for decades. The data and
experience are even more limited for newer, alternative second-
line intravenous treatment options, such as levetiracetam or
lacosamide. Further, the best quality evidence on the management
of RCSE is mostly derived from studies in adults41,47,49 with these
conclusions directly extrapolated to the clinical management of
RCSE in children, which might not always apply.88 Additionally,
dosing recommendations are based on limited observational databecause controlled trials comparing different doses are lacking,
even in adults.9
6.7. Timing of interventions
A timely escalation of antiepileptic drugs when initial treat-
ments fail is advocated.9,21,39,40,87,89–92 Basic research results14–
16,93–99 as well as clinical evidence5,6 suggests that the longer SE
persists, the more resistant it becomes to treatment. In a study of
157 children (1 month to 16 years of age) with SE, a treatment
delay of more than 30 min was associated with delayed seizure
control.100 In a study of 27 children, ﬁrst- (benzodiazepine) and
second-line (phenytoin or phenobarbital) medications were
effective in terminating SE in 86% when seizure duration was less
than 20 min at presentation and only in 15% when seizure duration
exceeded 30 min.101 The North London pediatric convulsive SE
population showed that for each minute delay from onset of SE to
arrival at the emergency department, there was a 5% cumulative
increase in the risk of the episode lasting more than 60 min.6
Together, these studies suggest that seizures must be treated
quickly before they become resistant to treatment and associated
with higher mortality.
As most cases of SE begin out-of-hospital, treatment plans for SE
should be easily applicable by families and school personnel
emphasizing the need of a timely intervention.50 A large series of
889 patients (625 adults and 264 children) categorized the timing
of administration of the ﬁrst antiepileptic drug as occurring in the
following broad time frames: 0–29, 30–59, 60–89, 90–119, 120–
179, 180–239, 240 min.102 Approximately 60% of the patients
received their ﬁrst medication after 30 min and 30% after 60 min
with no signiﬁcant differences between adults and children.102
However, to date there is a gap of pediatric and adult studies that
specify the timing of administration of the individual medications
and therefore there are no correlations between timing of
antiepileptic drug administration with outcome. As a consequence,
it is not possible to make evidence-based recommendations on
how fast antiepileptic drugs should be administered and when to
transition from one antiepileptic drug type to the next or whether
antiepileptic drugs should be given simultaneously.
7. The need of high-quality data to develop evidence-based
treatment strategies
Based on a formal series of discussions that culminated at the
Child Neurology Society and American Epilepsy Society meetings
in 2010, the pSERG was established. The guiding purpose of the
group is to delineate strategies for improving the management
and eventually the prognosis of children with SE, especially those
episodes that are not responsive to ﬁrst-line treatments and
become RCSE. The group concluded that in order to best
understand the relationship between variation in care and
outcome, pediatric SE data needed to be prospectively collected
and analyzed with a comparative effectiveness research ap-
proach.103,104 Furthermore, a large number of RCSE cases would
be necessary to:
(1) Describe how children with RCSE are currently managed in
clinical practice.
(2) Identify clinical ﬁndings, biomarkers, and treatment strategies
associated with more favorable outcomes (medication effec-
tiveness), and ultimately.
(3) Develop clinical predictors and biomarkers of care that permit
evidence-based clinical decision-making.
The number of RCSE cases needed for this scope of analysis is
beyond the capabilities of any individual center and is only feasible
Table 3
Summary of the main gaps in pediatric status epilepticus literature and how pSERG is aiming to address them.
Areas Main knowledge gaps in pediatric status epilepticus literature pSERG strategies to address these gaps
Epidemiology Clinical and genetic risk factors that contribute to refractoriness Genetic analyses of patients with RCSE
Correlation between etiology, response to different treatments
and long-term outcome
Long-term outcome evaluation with a particular focus in function and
neurocognitive function
Data on receptor changes during status epilepticus in human brain Collection of human brain samples from epilepsy surgery and autopsies
Long-term clinical and developmental sequelae and mortality Long-term follow-up with a focus on mortality and function
Diagnosis Indications and yield of lumbar puncture, toxicologic studies Collection of data on the yield of these tests when clinically used
Treatment Optimal ﬁrst-line therapy Comparative effectiveness of ﬁrst-line therapies
Optimal second-line therapy Comparative effectiveness of second-line therapies
Optimal third-line therapy Comparative effectiveness of third-line therapies
Optimal continuous infusion Comparative effectiveness of continuous infusions
Role of emerging therapies Descriptive analysis of the efﬁcacy of emerging therapies in a large
population
Timing and escalation of treatments Observational studies on the timing and escalation of drugs
Potential role of polytherapy and combinations of different
treatments
Descriptive analysis of the efﬁcacy of polytherapy when clinically used
Lack of comparative effectiveness studies Performance of comparative effectiveness studies
Lack of interventional treatment trials Performance of interventional treatment trials
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There is a general consensus in the adult and, especially pediatric
literature regarding the need for high-quality data on SE9,20,105
(Table 3). Randomized controlled trials are difﬁcult, but prospec-
tive observational study protocols assessing variation in care using
a comparative effectiveness approach are more feasible, help reﬁne
the key issues for future studies, and need to be developed.105
8. Goals of pSERG
The overall goal of pSERG is to foster an evidence based
approach to assessing the current variation in care and converting
that information to knowledge for improving the management and
prognosis of children with RCSE.103 The data obtained from
prospective collection of current clinical practice can inform future
decisions about care and treatment trials. This overall goal will be
attained by completing the following aims.
Aim 1. Build a standardized infrastructure that fosters
collaboration between hospitals that care for children with RCSE
by introducing common measurement indicators, common
terminology for documenting care, and a computerized online
database that facilitates data entry, data maintenance, and data
analysis.
Aim 2. Generate observational data on current acute care of
children with RCSE, including collection and analysis of clinical
data, treatment approaches, electroencephalography (EEG) ﬁnd-
ings, magnetic resonance imaging (MRI) ﬁndings, and biological
specimens in order to identify biomarkers and predictors of
treatment response and short-term outcome based on variation in
care.
Aim 3. Record and analyze observational data on the follow-up
of children with RCSE in order to identify biomarkers and
predictors of treatment response and long-term outcome based
on variation in care.
These three inter-related and ongoing aims will inform
evidence-based treatment approaches, and will provide informa-
tion on areas of greatest need for interventional treatment trials.104
9. Development of the pSERG network
Since December 2010, phone and in-person conferences have
been established in order to assign speciﬁc tasks, share problem-
solving strategies, update the group on achieved objectives, and
constitute a forum for exchange of ideas. Currently, the group is
composed of 12 tertiary care hospitals with large patientpopulations and infrastructure to diagnose, treat and study RCSE
(Supplementary Table S1).
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.seizure.
2013.10.004.
The organizational structure of pSERG (Supplementary Fig. S2)
consists of different committees and promotes involvement of
participants from each center and development of ancillary
studies. The executive committee establishes lines of research
inquiry and maintains a research infrastructure that facilitates data
collection. The database management working group facilitates data
entry and data analysis by creating and updating a computerized
web-based database. The quality control working group ensures that
the information in the database is as complete as possible and that
all the included RCSE episodes meet the inclusion/exclusion
criteria.
Supplementary material related to this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.seizure.
2013.10.004.
The data collection and publication working group oversees data
analysis and distributes data collected among the different
investigators in order to promote optimal analysis, timely
dissemination of results, and fair distribution of authorship. The
operations advisory working group assures that the research is
conducted according to ethical guidelines and that complies with
the Institutional Review Board (IRB) requirements at all centers.
10. Development of a computerized database with common
terminology
A secure, Health Insurance Portability and Accountability ACT
(HIPPA)-compliant web-based interface is used to promote
multicenter, anonymized data entry. This system is designed with
the same approach implemented by the Childhood Absence
Epilepsy Study Group106 and in Cincinnati Children’s Hospital
Medical Center’s Comprehensive Epilepsy Center. A modular plug-
and-play approach ensures generalizability of data while allowing
appropriate enhancements. Our web-based data entry and
management system uses MySQL, an open-source database
management system and CHRISTINE, a web-based data collection
system developed for multi-site neuropsychiatric research.107
Based on NIH/NINDS common data elements and case reports
forms for epilepsy (http://www.commondataelements.ninds.nih.
gov/epilepsy.aspx#tab=Data_Standards),108 the pSERG network
has developed a set of demographic, clinical, EEG, neuroimaging,
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pediatric RCSE diagnosis, management and outcome.
11. Patients
11.1. Inclusion/exclusion criteria
Patients with RCSE are eligible if they: (1) are between 1 month
to 21 years of age, (2) have convulsive seizures at onset, and (3)
experience failure of two or more antiepileptic drugs or require a
continuously administered medication to stop seizures
(Table 1).9,20,109 Patients are excluded if they: (1) have non-
convulsive SE detected on EEG only (without convulsive seizures at
onset) or (2) have non-convulsive SE with infrequent myoclonic
jerks. Patients with complex partial SE were included as long as
they had convulsive movements at onset.
We include age ranges from 1 month to 21 years in order to
exclude both neonates and older adults in whom the etiology,
natural history, and prognosis appear to follow a different
trajectory than in children.28,110 We deﬁne SE as prolonged self-
sustaining seizures and classiﬁed the episode of SE as ‘‘continuous’’
if there was a continuous clinical seizure or ‘‘intermittent’’ if there
were repeated clinical seizures without interval return to
baseline.12 We deﬁne RCSE as prolonged seizures that fail to
terminate after administration of two antiepileptic drugs with
different mechanisms of action or if a continuous medication
infusion was commenced to abort seizures, independent of seizure
duration.9,20,109 For the purposes of antiepileptic drug assessment,
different benzodiazepines given as a bolus (for example, rectal
diazepam followed by intravenous lorazepam) are counted as one
antiepileptic drug. The rationale for this decision is that different
benzodiazepines administered by different routes do not have
differences in mechanism of action or efﬁcacy.41,47,49 Benzodia-
zepines in continuous administration (for example, continuous
infusion of midazolam) are quantiﬁed as continuous medication
administration.
11.2. Collection of clinical information
Episodes of RCSE are prospectively identiﬁed at each center
through daily review of admissions to the Neurology services and
Neurology consultations in the emergency department and
intensive care unit as well as through collaboration with inpatient
care teams. The process of patient identiﬁcation varies little
between institutions to adjust for individual service designs. In
order to collect all pSERG variables, medical records are reviewed
during the hospitalization and, if deemed necessary, directed
interviews with the family and medical team are performed. Study
variables are de-identiﬁed by the study personnel at each
individual center and entered into the secure centralized database.
Management decisions are made by individual caretakers, para-
medics, and treating physicians, with no inﬂuence from the
research team. There is currently no speciﬁc management protocol
for the study and each center/provider cared for the patient based
on their own clinical decision-making strategies. The Institutional
Review Boards at each center approved the performance of this
study and each individual patient signed the consent form.
12. Ongoing projects
Considering the above summarized gaps in literature, the group
has now started clinical data collection within this database and
variables are being analyzed to generate and disseminate results
on the following topics.
How are children with RCSE managed in clinical practice? While
literature recommendations on treatment of SE abound, there isremarkable lack of data addressing antiepileptic drug choices,
dosing, and on the timing of antiepileptic drug administration in
real clinical management of pediatric RCSE9,21,40 We will describe
antiepileptic drug choices, and their timing of administration.
EEG monitoring ﬁndings. We will analyze EEG ﬁndings and in
conjunction with the pediatric critical care EEG group (PCCEG) will
identify neurophysiological biomarkers that inﬂuence care and
predict outcome.
Neuroimaging. We will describe neuroimaging ﬁndings to
identify imaging criteria that help inﬂuence care and predict
outcome.
Continuous medication administration, PICU management and
complications. In close collaboration with neurointensivists, we
will describe the management of RCSE in the ICU and, speciﬁcally
the use of continuous infusions to identify factors that inﬂuence
management and prognosis.
Short-term outcome in RCSE and identiﬁcation of risk factors. We
will describe the clinical and developmental outcomes in our
patients and will aim to identify the different treatment strategies
associated with better outcomes through comparative effective-
ness.104 Children with RCSE are historically difﬁcult to enroll in
randomized clinical trials for ethical and/or organizational reasons
including the lack of strong observational data in children in which
to base clinical trials, and thus this observational study design is
likely the best ﬁt for this rare but important disease process.104
Although clinical trials are considered the best available evidence,
comparative effectiveness incorporates the complexities and
vagaries of real-life clinical practice across a wide range of
patients.104
Long-term outcome. We will follow-up our cohort and will
describe the long-term outcome in terms of subsequent seizure
and SE occurrence, neurocognitive features, and disability rates in
RCSE survivors.
Genetic predisposition. pSERG is collaborating with The Duke
Center for Human Genomic Variation (CHGV) to collect blood
samples from our population of children with RCSE in order to
identify variants associated with a higher risk of self-sustaining
and pharmacologically intractable seizures. The Duke CHGV also
runs the Sequencing, Biostatistics, and Bioinformatics core of the
NIH-funded Epilepsy Center without Walls Human Genetic
Initiative called Ep4 K and it is anticipated that the pSERG
consortium will also collaborate with Ep4 K consortium in studies
of genetic predisposition. The study of genetic risk factors for a
certain condition beneﬁts from the evaluation of genotypes of both
affected and unaffected family members. Therefore, we will collect
and keep information on the occurrence of epilepsy and SE in the
parents and siblings of children with RCSE and we will collect
blood samples from these family members. We will also request
permission from the families to re-contact them in case that a more
detailed phenotype and genotype study is deemed of scientiﬁc
interest within a particular family.
13. Challenges and progress
During the development of this network we faced challenges
regarding the development of a common terminology, the
implementation of common inclusion and exclusion criteria, and
the development and optimization of a centralized database. We
decided to implement the NIH/NINDS common data elements for
epilepsy, and will continue to implement the newly developed NIH
Toolbox and PROMIS (http://www.nihpromis.org/?AspxAutoDe-
tectCookieSupport=1). This approach will not only satisfy the need
for a common language within our research network, but will
generate literature with a terminology that has been developed for
the mutual understanding of different subspecialties in neurology
and that is expected to become standard in the coming years. The
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interactive process. The development of a centralized database
implies frequent communication between the different clinical
centers and the database management working group. Release of
several preliminary formats of the database with a feedback and
optimization loop from the different participating centers was
necessary to achieve a fully functional and optimized database. We
have launched the pSERG project in the United States of America.
However, pediatric status epilepticus is a medical emergency that
occurs in all regions of the world and we sincerely hope that our
experience will alert other centers and fuel the development of
similar collaborative research networks in other regions of the
world that may eventually connect with pSERG.
14. Conclusions
pSERG is a research consortium that prospectively collects
standardized data from a large population of children with RCSE to
generate a high-quality data and biomarker repository that will
provide much needed information on variation of care in RCSE, and
will assess outcomes based on this variation. The strength of the
pSERG network derives from the collaboration to identify a large
number of patients in a relatively short time period including
prospective clinical data, continuous EEG monitoring, neuroimag-
ing, genetic information and ultimately the ability to implement
interventional clinical trials at multiple sites. The overall purpose is
to improve the management and ultimately the prognosis of
children with SE.
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